Article Text

Download PDFPDF
Refractory schizophrenia: adding aripiprazole to clozapine reduces negative but not overall symptoms

Statistics from



Does aripiprazole improve the antipsychotic effect of clozapine without increasing the risk of major adverse events in people with refractory schizophrenia?


61 Korean people, aged 18–65 years, with DSM-IV schizophrenia, a history of treatment failure, partial responsiveness to long term clozapine therapy (⩾1 year) and taking a stable clozapine dose for at least 3 months. Treatment failure was defined as persistent psychotic symptoms after at least two different antipsychotics at equivalent to ⩾600 mg/day chlorpromazine for ⩾6 weeks. Participants had to have a Brief Psychiatric Rating Scale (BPRS) score of ⩾35 or >2 global rating items on the Schedule for Assessment of Negative Symptoms (SANS) score ⩾3 (see online notes for exclusion criteria).


Refractory Schizophrenia Clinic, Seoul National University, Republic of Korea. Recruitment 1 December 2005 to 10 December 2006.


Aripiprazole (5–30 mg/day) or placebo for 8 weeks. An initial dose of 5 mg/day aripiprazole was administered and increased to 10 mg/day at 1 week. If …

View Full Text


  • Source of funding: Brain Research Centre of the 21st Century Frontier Research Program, Ministry of Science and Technology, Republic of Korea.


  • Competing interests: GR has received research funding from Novartis Canada and Merck Germany.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.